The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome

Nelke C, Schulte-Mecklenbeck A, Pawlitzki M, Rolfes L, Räuber S, Gross CC, Minnerup J, Meuth SG, Wiendl H, Ruck T

Forschungsartikel (Zeitschrift) | Peer reviewed

Zusammenfassung

While posterior reversible encephalopathy syndrome (PRES) is often characterized by an inflammatory cerebrospinal-fluid (CSF) profile, knowledge of immune cell patterns in PRES is lacking. Thus, we retrospectively characterized CSF and peripheral blood (PB) from 15 PRES patients, which we analyzed by multidimensional flow cytometry (FC). Results were compared to 72 controls, as well as to 9 patients with progressive multifocal leukoencephalopathy (PML, as a relevant differential diagnosis) and 15 multiple sclerosis patients (MS, as a classical neuroinflammatory disorder), respectively. Total protein level in CSF from PRES patients was elevated compared to that in controls, but not to MS and PML. In-depth FC analysis revealed no differences for adaptive immune cells (B cells, plasma cells, CD4+, and CD8+ T cells) in PB or CSF of PRES compared to controls. In contrast, we observed alterations of the adaptive immune response in CSF of PML and MS compared to PRES, indicating that the adaptive immune response is not a driver of disease in PRES. Indeed, PRES was characterized by an innate immune response with CD14++/CD16+ (intermediate) monocytes elevated in PB and CSF, while CD14++/CD16- (classical) monocytes were decreased in PB from PRES patients as compared to controls. Levels of CD14++/CD16+ monocytes correlated with the duration of hospital stay as a surrogate marker for disease severity in PRES patients. Our findings argue for a role of innate rather than adaptive immunity in the pathophysiology of PRES. The observed shift in monocyte subsets might provide valuable diagnostic clues for the clinical management of these patients.

Details zur Publikation

FachzeitschriftJournal of Clinical Immunology (J Clin Immunol)
Jahrgang / Bandnr. / Volume2021
StatusVeröffentlicht
Veröffentlichungsjahr2021
Sprache, in der die Publikation verfasst istEnglisch
DOI10.1007/s10875-021-01033-3

Autor*innen der Universität Münster

Schulte-Mecklenbeck, Andreas
Klinik für Neurologie mit Institut für Translationale Neurologie